Abstract
Chronic myelogenous leukemia, BCR-ABL1+ (CML) is a myeloproliferative neoplasm characterized by a BCRABL fusion gene and almost always exhibits the characteristic cytogenetic finding t(9;22)(q34;q11). The protein product of BCR-ABL1 is a constitutively active tyrosine kinase whose function is intrinsic to CML pathogenesis. Patients present with leukocytosis and often splenomegaly and prominent marrow hypercellularity with marked myeloid hyperplasia and basophilia in most cases. Unlike acute leukemias, the neoplastic myeloid cells in CML exhibit a full spectrum of maturation at the early stages of disease, but if untreated CML inexorably progresses to an acute leukemia. The recent development BCR-ABL1 tyrosine-kinase inhibitors has profoundly changed the clinical course of patients with CML; most patients achieve long-term remissions if they are treated in the early part of the disease course. Monitoring of resistance to tyrosine-kinase inhibitors and assessment for disease progression are critical in current CML management. Therapeutic approaches, including targeted therapy, is discussed.
Keywords: Chronic myelogenous leukemia, chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, imatinib, tyrosine kinase inhibitors, myeloproliferative neoplasms
Current Cancer Therapy Reviews
Title: Chronic Myelogenous Leukemia
Volume: 8 Issue: 1
Author(s): Robert P. Hasserjian
Affiliation:
Keywords: Chronic myelogenous leukemia, chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, imatinib, tyrosine kinase inhibitors, myeloproliferative neoplasms
Abstract: Chronic myelogenous leukemia, BCR-ABL1+ (CML) is a myeloproliferative neoplasm characterized by a BCRABL fusion gene and almost always exhibits the characteristic cytogenetic finding t(9;22)(q34;q11). The protein product of BCR-ABL1 is a constitutively active tyrosine kinase whose function is intrinsic to CML pathogenesis. Patients present with leukocytosis and often splenomegaly and prominent marrow hypercellularity with marked myeloid hyperplasia and basophilia in most cases. Unlike acute leukemias, the neoplastic myeloid cells in CML exhibit a full spectrum of maturation at the early stages of disease, but if untreated CML inexorably progresses to an acute leukemia. The recent development BCR-ABL1 tyrosine-kinase inhibitors has profoundly changed the clinical course of patients with CML; most patients achieve long-term remissions if they are treated in the early part of the disease course. Monitoring of resistance to tyrosine-kinase inhibitors and assessment for disease progression are critical in current CML management. Therapeutic approaches, including targeted therapy, is discussed.
Export Options
About this article
Cite this article as:
P. Hasserjian Robert, Chronic Myelogenous Leukemia, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462486
DOI https://dx.doi.org/10.2174/157339412799462486 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Piecing the Fragments Together: Dynamical Insights into the Enhancement
of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy
Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology The Challenge of Exploiting ABCG2 in the Clinic
Current Pharmaceutical Biotechnology Trends in Cell-Based Electrochemical Biosensors
Current Medicinal Chemistry Antibody-Based Preventive and Therapeutic Strategies Against HIV
Current HIV Research The Structure and Function of Histone Deacetylases: The Target for Anti-cancer Therapy
Current Medicinal Chemistry Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets Identification of Drug Candidates for Breast Cancer Therapy Through Scaffold Repurposing: A Brief Review
Current Drug Research Reviews Electrochemical Indicators for DNA Electroanalysis
Current Analytical Chemistry 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Clear Cell Renal Cell Cancer Tumor-Propagating Cells: Molecular Characteristics
Current Signal Transduction Therapy Chemistry and Health Effects of Bioactive Compounds in Selected Culinary Aromatic Herbs
Current Nutrition & Food Science Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents
Current Signal Transduction Therapy Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Maximizing Baculovirus-Mediated Foreign Proteins Expression in Mammalian Cells
Current Gene Therapy miRNAs in Bone Development
Current Genomics Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology